FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Moore

Research Profile

Living Beings

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Jean-Philippe Julien; Umesh Katpally; Reza Khayat; Jeong Hyun Lee; Andre J Marozsan; Ryan McBride; John P Moore; James C Paulson; Robert Pejchal; Pascal Poignard; Alejandra Ramos; Rogier W Sanders; Devin Sok; Robyn L Stanfield; Laura M Walker; Andrew B Ward; Dennis R Burton; Albert Cupo; Rafael S Depetris; Devan C Diwanji; Katie J Doores; Ian A Wilson
Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans.
Katie Matthews; John P Moore; Nancy P-Y Chung; Per Johan Klasse; Rogier W Sanders
Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation.
Nancy P-Y Chung; Per Johan Klasse; Katie Matthews; Rogier W Sanders; John P Moore
HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Moore (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jean-Philippe Julien; Umesh Katpally; Reza Khayat; Jeong Hyun Lee; Andre J Marozsan; Ryan McBride; John P Moore; James C Paulson; Robert Pejchal; Pascal Poignard; Alejandra Ramos; Rogier W Sanders; Devin Sok; Robyn L Stanfield; Laura M Walker; Andrew B Ward; Dennis R Burton; Albert Cupo; Rafael S Depetris; Devan C Diwanji; Katie J Doores; Ian A Wilson
Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans.
PLoS pathogens 2013;9(5):e1003342.
2012: Katie Matthews; John P Moore; Nancy P-Y Chung; Per Johan Klasse; Rogier W Sanders
Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation.
Journal of immunology (Baltimore, Md. : 1950) 2012;189(12):5729-44.
2012: Nancy P-Y Chung; Per Johan Klasse; Katie Matthews; Rogier W Sanders; John P Moore
HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 2012;189(11):5257-65.
2012: Rafael S Depetris; Jean-Philippe Julien; Milind Kachare; Umesh Katpally; Reza Khayat; Jeong Hyun Lee; Andre J Marozsan; Evan Massi; William C Olson; Robert Pejchal; Rogier W Sanders; Andrew B Ward; Ian A Wilson; Nicolette Cocco; Albert Cupo; Kathryn B David; John P Moore
Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.
The Journal of biological chemistry 2012;287(29):24239-54.
2012: Cleo G Anastassopoulou; Thomas J Ketas; Rogier W Sanders; Per Johan Klasse; John P Moore
Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.
Virology 2012;428(2):86-97.
2012: Reem Berro; Per Johan Klasse; John P Moore; Paul R Gorry; Martin R Jakobsen; Rogier W Sanders
V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.
Virology 2012;427(2):158-65.
2012: Dan H Barouch; Jason Dufour; Per Johan Klasse; Ronald S Veazey; John P Moore
Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(22):8694-8.
2012: John P Moore
HIV-1 Env antibodies: are we in a bind or going blind?
Nature medicine 2012;18(3):346-7; author reply 347-8.
2012: Kaustuv Banerjee; Dirk Eggink; Amanda B Lasnik; Elizabeth Michael; John P Moore; Kenneth E Palmer; Rogier W Sanders; Thijs van Montfort; Per Johan Klasse
Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.
AIDS research and human retroviruses 2012;28(2):206-14.
2012: Per Johan Klasse; John P Moore
Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines.
Retrovirology 2012;9():80.
2010: Ronald S Veazey; Thomas J Ketas; Jason Dufour; Terri Moroney-Rasmussen; Linda C Green; Per Johan Klasse; John P Moore
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.
The Journal of infectious diseases 2010;202(5):739-44.
2010: John P Moore
Misconduct: don't penalize the honest majority of scientists.
Nature 2010;466(7310):1040.
2010: Robert J Kaner; Francisco Santiago; Franck Rahaghi; Elizabeth Michaels; John P Moore; Ronald G Crystal
Adenovirus vectors block human immunodeficiency virus-1 replication in human alveolar macrophages by inhibition of the long terminal repeat.
American journal of respiratory cell and molecular biology 2010;43(2):234-42.
2010: Kaustuv Banerjee; Per Johan Klasse; Rogier W Sanders; Florencia Pereyra; Elizabeth Michael; Min Lu; Bruce D Walker; John P Moore
IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.
AIDS research and human retroviruses 2010;26(4):445-58.
2010: Jie Liu; Yiqun Deng; Qunnu Li; Dey Antu; John P Moore; Min Lu
Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion.
Journal of virology 2010;84(1):201-9.
2009: Yun Kenneth Kang; Sofija Andjelic; James M Binley; Emma T Crooks; Michael Franti; Sai Prasad N Iyer; Gerald P Donovan; Dey Antu; Ping Zhu; Kenneth H Roux; Robert J Durso; Thomas F Parsons; Paul J Maddon; John P Moore; William C Olson
Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.
Vaccine 2009;27(37):5120-32.
2009: Reem Berro; Rogier W Sanders; Min Lu; Per Johan Klasse; John P Moore
Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.
PLoS pathogens 2009;5(8):e1000548.
2009: Kaustuv Banerjee; Sofija Andjelic; Per Johan Klasse; Yun Kang; Rogier W Sanders; Elizabeth Michael; Robert J Durso; Thomas J Ketas; William C Olson; John P Moore
Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.
Virology 2009;389(1-2):108-21.
2009: Pavel Pugach; Neelanjana Ray; Per Johan Klasse; Thomas J Ketas; Elizabeth Michael; Robert W Doms; Benhur Lee; John P Moore
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.
Virology 2009;387(2):296-302.
2009: Jie Liu; Yiqun Deng; Dey Antu; John P Moore; Min Lu
Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation.
Biochemistry 2009;48(13):2915-23.
2009: Cleo G Anastassopoulou; Thomas J Ketas; Per Johan Klasse; John P Moore
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(13):5318-23.
2009: Dey Antu; Kathryn B David; Min Lu; John P Moore
Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins.
Virology 2009;385(1):275-81.
2008: Pavel Pugach; Thomas J Ketas; Elizabeth Michael; John P Moore
Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.
Virology 2008;377(2):401-7.
2008: Ronald S Veazey; Thomas A Ketas; Per Johan Klasse; Donna K Davison; Morgan Singletary; Linda C Green; Michael L Greenberg; John P Moore
Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(30):10531-6.
2008: John P Moore; P J Klasse; Matthew J Dolan; Sunil Ahuja
AIDS/HIV. A STEP into darkness or light?
Science (New York, N.Y.) 2008;320(5877):753-5.
2008: Dey Antu; Kathryn B David; Neelanjana Ray; Thomas J Ketas; Per Johan Klasse; Robert W Doms; John P Moore
N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.
Virology 2008;372(1):187-200.
2007: John P Moore; Per Johan Klasse
HIV-1 pathogenesis: the complexities of the CCR5-CCL3L1 complex.
Cell host & microbe 2007;2(5):281-3.
2007: Meimei Shan; Per Johan Klasse; Kaustuv Banerjee; Dey Antu; Sai Prasad N Iyer; Robert Dionisio; Dustin Charles; Lila Campbell-Gardener; William C Olson; Rogier W Sanders; John P Moore
HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells.
PLoS pathogens 2007;3(11):e169.
2007: Thomas J Ketas; Shawn E Kuhmann; Ashley Palmer; Juan Zurita; Weijing He; Sunil Ahuja; Per Johan Klasse; John P Moore
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.
Virology 2007;364(2):281-90.
2007: Thomas J Ketas; Susan M Schader; Juan Zurita; Esther Teo; Victoria R Polonis; Min Lu; Per Johan Klasse; John P Moore
Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.
Virology 2007;364(2):431-40.
2007: Sai Prasad N Iyer; Michael Franti; Ammie A Krauchuk; Danielle N Fisch; Amadou A Ouattara; Kenneth H Roux; Laura Krawiec; Dey Antu; Simon Beddows; Paul J Maddon; John P Moore; William C Olson
Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers.
AIDS research and human retroviruses 2007;23(6):817-28.
2007: Cleo G Anastassopoulou; Andre J Marozsan; Alexandre Matet; Amy D Snyder; Eric J Arts; Shawn E Kuhmann; John P Moore
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss.
PLoS pathogens 2007;3(6):e79.
2007: Paul R Gorry; Rebecca L Dunfee; Megan Mefford; Kevin Kunstman; Tom Morgan; John P Moore; John R Mascola; Kristin Agopian; Geoffrey Holm; Andrew Mehle; Joann Taylor; Michael Farzan; Hui Wang; Philip Ellery; Samantha Willey; Paul R Clapham; Steven Wolinsky; Suzanne M Crowe; Dana Gabuzda
Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.
Virology 2007;362(1):163-78.
2007: Pavel Pugach; Andre J Marozsan; Thomas J Ketas; Elissa L Landes; John P Moore; Shawn E Kuhmann
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.
Virology 2007;361(1):212-28.
2007: Yiqun Deng; Qi Zheng; Thomas J Ketas; John P Moore; Min Lu
Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Biochemistry 2007;46(14):4360-9.
2007: Simon Beddows; Michael Franti; Dey Antu; Marc Kirschner; Sai Prasad N Iyer; Danielle C Fisch; Thomas J Ketas; Eloisa Yuste; Ronald C Desrosiers; Per Johan Klasse; Paul J Maddon; William C Olson; John P Moore
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
Virology 2007;360(2):329-40.
2007: Dey Antu; Kathryn B David; Per Johan Klasse; John P Moore
Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.
Virology 2007;360(1):199-208.
2006: Per Johan Klasse; Robin J Shattock; John P Moore
Which topical microbicides for blocking HIV-1 transmission will work in the real world?
PLoS medicine 2006;3(9):e351.
2006: Carolina Herrera; Per Johan Klasse; Christopher W Kibler; Elizabeth Michael; John P Moore; Simon Beddows
Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex.
Virology 2006;351(1):121-32.
2006: Marc Kirschner; Val Monrose; Maciej Paluch; Nipa Techodamrongsin; Axel Rethwilm; John P Moore
The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent.
Protein expression and purification 2006;48(1):61-8.
2006: Simon Beddows; Marc Kirschner; Lila Campbell-Gardener; Michael Franti; Dey Antu; Sai Prasad N Iyer; Paul J Maddon; Maciej Paluch; Aditi Master; Julie Overbaugh; Thomas C VanCott; William C Olson; John P Moore
Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A.
AIDS research and human retroviruses 2006;22(6):569-79.
2006: Christoph Seibert; Weiwen Ying; Svetlana Gavrilov; Fotini Tsamis; Shawn E Kuhmann; Anandan Palani; Jayaram R Tagat; John W Clader; Stuart W McCombie; Bahige M Baroudy; Steven O Smith; Tanya Dragic; John P Moore; Thomas P Sakmar
Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
Virology 2006;349(1):41-54.
2005: Ronald S Veazey; Martin S Springer; Preston A Marx; Jason Dufour; Per Johan Klasse; John P Moore
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor.
Nature medicine 2005;11(12):1293-4.
2005: Ronald S Veazey; Per Johan Klasse; Susan M Schader; Qinxue Hu; Thomas J Ketas; Min Lu; Preston A Marx; Jason Dufour; Richard J Colonno; Robin J Shattock; Martin S Springer; John P Moore
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.
Nature 2005;438(7064):99-102.
2005: Tonie Cilliers; Samantha Willey; W Matthew Sullivan; Trudy Patience; Pavel Pugach; Mia Coetzer; Maria A Papathanasopoulos; John P Moore; Alexandra Trkola; Paul R Clapham; Lynn Morris
Use of alternate coreceptors on primary cells by two HIV-1 isolates.
Virology 2005;339(1):136-44.
2005: Andre J Marozsan; Shawn E Kuhmann; Thomas Morgan; Carolina Herrera; Enid Rivera-Troche; Serena Xu; Bahige M Baroudy; Julie M Strizki; John P Moore
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Virology 2005;338(1):182-99.
2005: Carolina Herrera; Per Johan Klasse; Elizabeth Michael; Shivani Kake; Kelly Barnes; Christopher W Kibler; Lila Campbell-Gardener; Zhihai Si; Joseph Sodroski; John P Moore; Simon Beddows
The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles.
Virology 2005;338(1):154-72.
2005: Simon Beddows; Norbert Schülke; Marc Kirschner; Kelly Barnes; Michael Franti; Elizabeth Michael; Thomas J Ketas; Rogier W Sanders; Paul J Maddon; William C Olson; John P Moore
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
Journal of virology 2005;79(14):8812-27.
2005: Simon Beddows; Natalie N Zheng; Carolina Herrera; Elizabeth Michael; Kelly Barnes; John P Moore; Rod S Daniels; Jonathan N Weber
Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability.
Virology 2005;337(1):136-48.
2005: John P Moore
Topical microbicides become topical.
The New England journal of medicine 2005;352(3):298-300.
2004: Steven Wolinsky; Ronald S Veazey; Kevin Kunstman; Per Johan Klasse; Jason Dufour; Andre J Marozsan; Martin S Springer; John P Moore
Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses.
Virology 2004;328(1):19-29.
2004: John P Moore; Dennis R Burton
Urgently needed: a filter for the HIV-1 vaccine pipeline.
Nature medicine 2004;10(8):769-71.
2004: Rogier W Sanders; Els Busser; John P Moore; Min Lu; Ben Berkhout
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure.
AIDS research and human retroviruses 2004;20(7):742-9.
2004: Per Johan Klasse; John P Moore
Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects?
Virology 2004;323(1):1-8.
2004: Erika Billick; Christoph Seibert; Pavel Pugach; Thomas J Ketas; Alexandra Trkola; Michael J Endres; Nicholas J Murgolo; Elizabeth Coates; Gregory R Reyes; Bahige M Baroudy; Thomas P Sakmar; John P Moore; Shawn E Kuhmann
The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors.
Journal of virology 2004;78(8):4134-44.
2004: Pavel Pugach; Shawn E Kuhmann; Joann Taylor; Andre J Marozsan; Amy Snyder; Thomas J Ketas; Steven Wolinsky; Bette T Korber; John P Moore
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
Virology 2004;321(1):8-22.
2004: Shawn E Kuhmann; John P Moore
HIV-1 entry inhibitor entrances.
Trends in pharmacological sciences 2004;25(3):117-20.
2004: Shawn E Kuhmann; Pavel Pugach; Kevin Kunstman; Joann Taylor; Robyn L Stanfield; Amy Snyder; Julie M Strizki; Janice Riley; Bahige M Baroudy; Ian A Wilson; Bette T Korber; Steven Wolinsky; John P Moore
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
Journal of virology 2004;78(6):2790-807.
2004: Jeffrey M Jacobson; Robert J Israel; Israel Lowy; Nancy A Ostrow; Linda S Vassilatos; Melanie Barish; Diep N H Tran; Brian M Sullivan; Thomas J Ketas; Tobias J O'Neill; Kirsten A Nagashima; Wei Huang; Christos J Petropoulos; John P Moore; Paul J Maddon; William C Olson
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.
Antimicrobial agents and chemotherapy 2004;48(2):423-9.
2004: Rogier W Sanders; Martijn M Dankers; Els Busser; Michael Caffrey; John P Moore; Ben Berkhout
Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41.
Retrovirology 2004;1():3.
2004: John P Moore; Scott Kitchen; Pavel Pugach; Jerome A Zack
The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection.
AIDS research and human retroviruses 2004;20(1):111-26.
2003: John P Moore; Robin J Shattock
Preventing HIV-1 sexual transmission--not sexy enough science, or no benefit to the bottom line?
The Journal of antimicrobial chemotherapy 2003;52(6):890-2.
2003: Ronald S Veazey; Per Johan Klasse; Thomas J Ketas; Jacqueline D Reeves; Michael Piatak; Kevin Kunstman; Shawn E Kuhmann; Preston A Marx; Jeffrey D Lifson; Jason Dufour; Megan Mefford; Ivona Pandrea; Steven Wolinsky; Robert W Doms; Julie A DeMartino; Salvatore J Siciliano; Kathy Lyons; Martin S Springer; John P Moore
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.
The Journal of experimental medicine 2003;198(10):1551-62.
2003: John P Moore; Robert W Doms
The entry of entry inhibitors: a fusion of science and medicine.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(19):10598-602.
2003: Branka Roscic-Mrkic; Marek Fischer; Christine Leemann; Amapola Manrique; Cynthia J Gordon; John P Moore; Amanda E I Proudfoot; Alexandra Trkola
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement.
Blood 2003;102(4):1169-77.
2003: Fotini Tsamis; Svetlana Gavrilov; Francis Kajumo; Christoph Seibert; Shawn E Kuhmann; Thomas J Ketas; Alexandra Trkola; Anandan Palani; John W Clader; Jayaram R Tagat; Stuart W McCombie; Bahige M Baroudy; John P Moore; Thomas P Sakmar; Tanya Dragic
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.
Journal of virology 2003;77(9):5201-8.
2003: Tonie Cilliers; Jabulani Nhlapo; Mia Coetzer; Dragana Orlovic; Thomas J Ketas; William C Olson; John P Moore; Alexandra Trkola; Lynn Morris
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.
Journal of virology 2003;77(7):4449-56.
2003: Thomas J Ketas; Per Johan Klasse; Catherine Spenlehauer; Mirjana Nesin; Ines Frank; Melissa Pope; Julie M Strizki; Gregory R Reyes; Bahige M Baroudy; John P Moore
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.
AIDS research and human retroviruses 2003;19(3):177-86.
2003: Ronald S Veazey; Robin J Shattock; Melissa Pope; J Christian Kirijan; Jennifer Jones; Qinxue Hu; Thomas J Ketas; Preston A Marx; Per Johan Klasse; Dennis R Burton; John P Moore
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.
Nature medicine 2003;9(3):343-6.
2003: Thomas J Ketas; Ines Frank; Per Johan Klasse; Brian M Sullivan; Jason P Gardner; Catherine Spenlehauer; Mirjana Nesin; William C Olson; John P Moore; Melissa Pope
Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.
Journal of virology 2003;77(4):2762-7.
2003: Carolina Herrera; Catherine Spenlehauer; Michael S Fung; Dennis R Burton; Simon Beddows; John P Moore
Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site.
Journal of virology 2003;77(2):1084-91.
2002: Rogier W Sanders; Mika S Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
Journal of virology 2002;76(17):8875-89.
2002: Joshua Rice; Ruth I Connor; Stefan Worgall; John P Moore; Philip L Leopold; Robert J Kaner; Helen-Ann Brown Epstein
Inhibition of HIV-1 replication in alveolar macrophages by adenovirus gene transfer vectors.
American journal of respiratory cell and molecular biology 2002;27(2):214-9.
2002: Norbert Schülke; Mika S Vesanen; Rogier W Sanders; Ping Zhu; Min Lu; Deborah J Anselma; Anthony R Villa; Paul W H I Parren; James M Binley; Kenneth H Roux; Paul J Maddon; John P Moore; William C Olson
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.
Journal of virology 2002;76(15):7760-76.
2002: Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.
Journal of virology 2002;76(14):7293-305.
2002: Paul R Gorry; Joann Taylor; Geoffrey Holm; Andrew Mehle; Tom Morgan; Mark Cayabyab; Michael Farzan; Hui Wang; Jeanne E Bell; Kevin Kunstman; John P Moore; Steven Wolinsky; Dana Gabuzda
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.
Journal of virology 2002;76(12):6277-92.
2002: James M Binley; Rogier W Sanders; Aditi Master; Charmagne S Cayanan; Cheryl Wiley; Linnea Schiffner; Bruce Travis; Shawn E Kuhmann; Dennis R Burton; Shiu-Lok Hu; William C Olson; John P Moore
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.
Journal of virology 2002;76(6):2606-16.
2002: Theresa L Chang; Cynthia J Gordon; Branka Roscic-Mrkic; Christine Power; Amanda E I Proudfoot; John P Moore; Alexandra Trkola
Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity.
Journal of virology 2002;76(5):2245-54.
2002: John P Moore
AIDS vaccines: on the trail of two trials.
Nature 2002;415(6870):365-6.
2002: Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Thomas J Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram R Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart W McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(1):395-400.
2002: Theresa L Chang; Arevik Mosoian; Richard Pine; Mary E Klotman; John P Moore
A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation.
Journal of virology 2002;76(2):569-81.
2001: Carol Parker; Leesa J Deterding; Christine Hager-Braun; James M Binley; Norbert Schülke; Hermann Katinger; John P Moore; Kenneth B Tomer
Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.
Journal of virology 2001;75(22):10906-11.
2001: Julie M Strizki; Serena Xu; Nicole E Wagner; Lisa Wojcik; J Liu; Y Hou; Michael Endres; Anandan Palani; Sherry Shapiro; John W Clader; William J Greenlee; Jayaram R Tagat; Stuart W McCombie; Kathleen Cox; Ahmad Fawzi; Chuan-Chu Chou; Catherine Pugliese-Sivo; L Davies; Mary E Moreno; D D Ho; Alexandra Trkola; Cheryl A Stoddart; John P Moore; Gregory R Reyes; Bahige M Baroudy
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(22):12718-23.
2001: John P Moore; P W Parren; Dennis R Burton
Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.
Journal of virology 2001;75(13):5721-9.
2001: C Spenlehauer; C A Gordon; Alexandra Trkola; John P Moore
A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1.
Virology 2001;280(2):292-300.
2001: YJ Zhang; Linqi Zhang; Thomas J Ketas; Bette T Korber; John P Moore
HIV type 1 molecular clones able to use the Bonzo/STRL-33 coreceptor for virus entry.
AIDS research and human retroviruses 2001;17(3):217-27.
2001: Alexandra Trkola; Thomas J Ketas; K A Nagashima; L Zhao; Tonie Cilliers; Lynn Morris; John P Moore; Paul J Maddon; William C Olson
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Journal of virology 2001;75(2):579-88.
2000: Y Ye; Z H Si; John P Moore; Joseph Sodroski
Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.
Journal of virology 2000;74(24):11955-62.
2000: John P Moore; Mario Stevenson
New targets for inhibitors of HIV-1 replication.
Nature reviews. Molecular cell biology 2000;1(1):40-9.
2000: James M Binley; Alexandra Trkola; Thomas J Ketas; Daryl Schiller; BA Clas; S Little; D Richman; Arlene Hurley; Martin Markowitz; John P Moore
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.
The Journal of infectious diseases 2000;182(3):945-9.
2000: Y Zhang; B Lou; R B Lal; Agegnehu Gettie; Preston A Marx; John P Moore
Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.
Journal of virology 2000;74(15):6893-910.
2000: Rogier W Sanders; Linnea Schiffner; Aditi Master; Francis Kajumo; Y Guo; Tanya Dragic; John P Moore; James M Binley
Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.
Journal of virology 2000;74(11):5091-100.
2000: Tanya Dragic; Alexandra Trkola; Daniah A D Thompson; Emmanuel G Cormier; Francis Kajumo; Elizabeth Maxwell; SW Lin; W Ying; Steven O Smith; Thomas P Sakmar; John P Moore
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(10):5639-44.
2000: James M Binley; BA Clas; Agegnehu Gettie; Mika S Vesanen; David C Montefiori; L Sawyer; J Booth; M Lewis; Preston A Marx; Sebastian Bonhoeffer; John P Moore
Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia.
Virology 2000;270(1):237-49.
2000: James M Binley; Daryl Schiller; G M Ortiz; Arlene Hurley; Douglas F Nixon; Martin Markowitz; John P Moore
The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.
The Journal of infectious diseases 2000;181(4):1249-63.
2000: J J Martinson; L Hong; Rose Karanicolas; John P Moore; Leondios G Kostrikis
Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype.
AIDS (London, England) 2000;14(5):483-9.
2000: Daryl Schiller; James M Binley; Kenneth H Roux; Catherine S Adamson; Ian M Jones; H G Krausslich; Arlene Hurley; Martin Markowitz; John P Moore
Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection.
AIDS research and human retroviruses 2000;16(3):259-71.
2000: James M Binley; Rogier W Sanders; BA Clas; N Schuelke; Aditi Master; Y Guo; Francis Kajumo; Deborah J Anselma; Paul J Maddon; William C Olson; John P Moore
A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
Journal of virology 2000;74(2):627-43.
1999: Leondios G Kostrikis; Avidan U Neumann; B Thomson; Bette T Korber; P McHardy; Rose Karanicolas; L Deutsch; Yaoxing Huang; J F Lew; K McIntosh; Henry Pollack; William Borkowsky; Hans M L Spiegel; Paul Palumbo; James M Oleske; Arlene Bardeguez; Katherine Luzuriaga; John L Sullivan; Steven Wolinsky; RA Koup; David D Ho; John P Moore
A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants.
Journal of virology 1999;73(12):10264-71.
1999: Alexandra Trkola; J Matthews; C Gordon; Thomas J Ketas; John P Moore
A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.
Journal of virology 1999;73(11):8966-74.
1999: G M Ortiz; Douglas F Nixon; Alexandra Trkola; James M Binley; Xia Jin; Sebastian Bonhoeffer; P J Kuebler; Sean M Donahoe; MA Demoitie; WM Kakimoto; Thomas J Ketas; BA Clas; J J Heymann; Linqi Zhang; Yunzhen Cao; Arlene Hurley; John P Moore; David D Ho; Martin Markowitz
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.
The Journal of clinical investigation 1999;104(6):R13-8.
1999: Alexandra Trkola; C Gordon; J Matthews; Elizabeth Maxwell; Thomas J Ketas; Lloyd Czaplewski; Amanda E I Proudfoot; John P Moore
The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity.
Journal of virology 1999;73(8):6370-9.
1999: William C Olson; G E Rabut; Kirsten A Nagashima; Diep N H Tran; Deborah J Anselma; SP Monard; J P Segal; Daniah A D Thompson; Francis Kajumo; Y Guo; John P Moore; Paul J Maddon; Tanya Dragic
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.
Journal of virology 1999;73(5):4145-55.
1999: YJ Zhang; John P Moore
Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?
Journal of virology 1999;73(4):3443-8.
1999: Martin Markowitz; Mika S Vesanen; Klara Tenner-Racz; Yunzhen Cao; James M Binley; Andrew H Talal; Arlene Hurley; Xia Jin; M R Chaudhry; M Yaman; S Frankel; ME Heath-Chiozzi; JM Leonard; John P Moore; Paul Racz; Douglas F Nixon; David D Ho; X J
The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
The Journal of infectious diseases 1999;179(3):527-37.
1999: Cynthia J Gordon; M A Muesing; Amanda E I Proudfoot; C A Power; John P Moore; Alexandra Trkola
Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion.
Journal of virology 1999;73(1):684-94.
1998: YJ Zhang; Tanya Dragic; Yunzhen Cao; Leondios G Kostrikis; D S Kwon; Dan R Littman; Vineet N KewalRamani; John P Moore
Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro.
Journal of virology 1998;72(11):9337-44.
1998: Ruth I Connor; David C Montefiori; James M Binley; John P Moore; Sebastian Bonhoeffer; Agegnehu Gettie; E A Fenamore; KE Sheridan; David D Ho; Peter J Dailey; Preston A Marx
Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.
Journal of virology 1998;72(9):7501-9.
1998: L Morris; James M Binley; BA Clas; Sebastian Bonhoeffer; T P Astill; Rhonda Kost; Arlene Hurley; Yunzhen Cao; Martin Markowitz; David D Ho; John P Moore
HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy.
The Journal of experimental medicine 1998;188(2):233-45.
1998: H Mo; SP Monard; Henry Pollack; JE Ip; Gemma Rochford; L Wu; JA Hoxie; William Borkowsky; David D Ho; John P Moore
Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood.
AIDS research and human retroviruses 1998;14(7):607-17.
1998: TR Fouts; Alexandra Trkola; M S Fung; John P Moore
Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization.
AIDS research and human retroviruses 1998;14(7):591-7.
1998: James M Binley; Xia Jin; Yaoxing Huang; Linqi Zhang; Yunzhen Cao; David D Ho; John P Moore
Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression.
Journal of virology 1998;72(4):3472-4.
1998: G E Rabut; J A Konner; Francis Kajumo; John P Moore; Tanya Dragic
Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1.
Journal of virology 1998;72(4):3464-8.
1998: Leondios G Kostrikis; Yaoxing Huang; John P Moore; Steven Wolinsky; Linqi Zhang; Y Guo; L Deutsch; J Phair; Avidan U Neumann; David D Ho
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation.
Nature medicine 1998;4(3):350-3.
1998: Alexandra Trkola; Thomas J Ketas; Vineet N KewalRamani; F Endorf; James M Binley; Hermann Katinger; J Robinson; Dan R Littman; John P Moore
Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.
Journal of virology 1998;72(3):1876-85.
1998: James M Binley; Richard Wyatt; E Desjardins; Peter D Kwong; Wayne A Hendrickson; John P Moore; Joseph Sodroski
Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120.
AIDS research and human retroviruses 1998;14(3):191-8.
1998: Ruth I Connor; Bette T Korber; Barney S Graham; B H Hahn; David D Ho; B D Walker; Avidan U Neumann; Sten Vermund; J Mestecky; S Jackson; E Fenamore; Yunzhen Cao; F Gao; S Kalams; Kevin Kunstman; D McDonald; N McWilliams; Alexandra Trkola; John P Moore; Steven Wolinsky
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.
Journal of virology 1998;72(2):1552-76.
1998: G A Donzella; Dominique Schols; SW Lin; José A Esté; Kirsten A Nagashima; Paul J Maddon; GP Allaway; Thomas P Sakmar; Geoffrey Henson; Erik De Clercq; John P Moore
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.
Nature medicine 1998;4(1):72-7.
1998: Alexandra Trkola; William A Paxton; SP Monard; JA Hoxie; M A Siani; Daniah A D Thompson; L Wu; CR Mackay; richard horuk; John P Moore
Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.
Journal of virology 1998;72(1):396-404.
1998: Tanya Dragic; Alexandra Trkola; SW Lin; Kirsten A Nagashima; Francis Kajumo; L Zhao; William C Olson; L Wu; CR Mackay; GP Allaway; Thomas P Sakmar; John P Moore; Paul J Maddon
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.
Journal of virology 1998;72(1):279-85.
1997: Lijun Wu; Greg La Rosa; N Kassam; C J Gordon; HM Heath; N Ruffing; H Chen; J Humblias; M Samson; Marc Parmentier; John P Moore; CR Mackay
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.
The Journal of experimental medicine 1997;186(8):1373-81.
1997: Melissa Pope; Sarah Schlesinger Frankel; John R Mascola; Alexandra Trkola; F Isdell; Deborah L Birx; Donald S. Burke; David D Ho; John P Moore
Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism.
Journal of virology 1997;71(10):8001-7.
1997: H Mo; Leonidas Stamatatos; JE Ip; C F Barbas; Paul W H I Parren; Dennis R Burton; John P Moore; David D Ho
Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off.
Journal of virology 1997;71(9):6869-74.
1997: James M Binley; H Arshad; TR Fouts; John P Moore
An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1.
AIDS research and human retroviruses 1997;13(12):1007-15.
1997: John P Moore; Alexandra Trkola; Tanya Dragic
Co-receptors for HIV-1 entry.
Current opinion in immunology 1997;9(4):551-62.
1997: John P Moore
Coreceptors: implications for HIV pathogenesis and therapy.
Science (New York, N.Y.) 1997;276(5309):51-2.
1997: James M Binley; P J Klasse; Yunzhen Cao; I Jones; Martin Markowitz; David D Ho; John P Moore
Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.
Journal of virology 1997;71(4):2799-809.
1997: TR Fouts; James M Binley; Alexandra Trkola; J E Robinson; John P Moore
Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.
Journal of virology 1997;71(4):2779-85.